U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07516847) titled 'Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes' on April 01.
Brief Summary: This study is a prospective, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of dapagliflozin in improving anemia in patients with lower-risk myelodysplastic syndromes (MDS).
Anemia is the most common clinical problem in patients with lower-risk MDS and often leads to fatigue, reduced quality of life, and the need for repeated blood transfusions. Current treatment options, including erythropoiesis-stimulating agents and other therapies, are not effective in all patients, and additional treatment options are...